Patients are already feeling the effects of recently approved, novel cancer immunotherapy drugs such as Nivolaumb and Pembrolizaumb, but with each step forward, researchers are becoming increasingly aware of the complexity and unique challenges that come with each individual’s disease. These include the impact of an individual's microbiome and innate immune system, in addition to complexities coming from targeting the complex tumor microenvironment and discovering immunogenic neoantigens. Given that not all patients respond to existing treatments, there is an enormous need to look towards the next generation of immunotherapy solutions.

At Cambridge Healthtech Institute's Inaugural ImPACT: Immunotherapy Progress and Clinical Treatments, being held December 5-7, 2017 in San Diego, four cutting-edge conferences will showcase what’s coming next in immunotherapy. The four conference programs bring together emerging scientists in the fields of microbiome, neoantigens, innate immune cells and the tumor microenvironment for three days of the latest research, networking, and strategies to continue moving immunotherapies to the clinic. 


Manufacturing Chimeric Antigen Receptor T Cells for Early Phase Clinical Trials

David F. Stroncek, M.D.

Chief, Cell Therapy Section, Transfusion Medicine, NIH Clinical Center

Evolution of Cancer Immunotherapy

Ramy Ibrahim, M.D.

VP, Clinical Development, Parker Institute for Cancer Immunotherapy